




Instance: composition-en-8e3f73294a020fb836dccebb0eb47004
InstanceOf: CompositionUvEpi
Title: "Composition for firdapse Package Leaflet"
Description:  "Composition for firdapse Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8e3f73294a020fb836dccebb0eb47004)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - firdapse"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What FIRDAPSE is and what it is used for </li>
<li>What you need to know before you take FIRDAPSE </li>
<li>How to take FIRDAPSE </li>
<li>Possible side effects </li>
<li>How to store FIRDAPSE </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What firdapse is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What firdapse is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>FIRDAPSE is used to treat symptoms of a disease of the nerves and the muscles called Lambert-Eaton 
myasthenic syndrome or LEMS in adults. This disease is a disorder affecting the transmission of nerve 
impulses to muscles, resulting in muscle weakness. It can be associated with certain tumour types 
(paraneoplastic form of LEMS) or in the absence of these tumours (non-paraneoplastic form of 
LEMS). </p>
<p>In patients suffering from this disease, a chemical substance called acetylcholine, which communicates 
nerve impulses to muscles is not released normally and the muscle doesn't receive some or all of the 
nerve's signals.  </p>
<p>FIRDAPSE works by increasing the release of acetylcholine and helps the muscle to receive the nerve 
signals. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take firdapse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take firdapse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take FIRDAPSE 
If you are allergic to amifampridine, or any of the other ingredients of this medicine (listed in 
section 6) 
If you have uncontrolled asthma 
If you are epileptic 
Together with medicines that may change the electrical activity of your heart (QT-interval 
prolongation - detectable in the electrocardiogram), such as: 
Sultropride (a medicine prescribed to treat certain behavioural disorders in adults),<br />
Antiarrhythmic medicine (e.g., disopyramide)<br />
Medicines to treat digestive problems (e.g., cisapride, domperidone) 
Medicines to treat infections - antibiotics (e.g., rifampicin) and antifungals (e.g., ketoconazole) 
Together with medicines with a therapeutic dose close to the maximum safe dose 
If you were born with heart problems (congenital QT syndromes) </p>
<p>If you have any doubts, ask your doctor or pharmacist for advice. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking FIRDAPSE. </p>
<p>Tell your doctor if you have<br />
Asthma 
A history of fits (convulsions) 
Kidney problems 
Liver problems </p>
<p>Your doctor will monitor carefully how FIRDAPSE works for you and may need to change the dose 
of the medicines you take. Your doctor will also monitor your heart at the start of your treatment and 
also every year thereafter. </p>
<p>If you have LEMS but do not have cancer, your doctor will make a thorough assessment of the 
potential risk of cancer with FIRDAPSE before commencing treatment. </p>
<p>Tell any physician you consult that you are using FIRDAPSE. </p>
<p>Stop the treatment and immediately consult your doctor in the event of: 
Fits (convulsions) 
Asthma </p>
<p>Other medicines and FIRDAPSE 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Some medicines may interact with FIRDAPSE when taken together. The following medicines must 
not be combined with FIRDAPSE:<br />
Medicines that may change the electrical activity of your heart (QT-interval prolongation - detectable 
in the electrocardiogram) e.g., sultopride, disopyramide, cisapride, domperidone, rifampicin, and 
ketoconazole (see  Do not take FIRDAPSE ) </p>
<p>It is especially important to talk to your doctor if you are taking one of the following medicines or plan 
to start taking the following medicines: 
Medicines for malaria (e.g. halofantrine and mefloquine) 
Tramadol (a painkiller) 
Antidepressants - tricyclic antidepressants (e.g. clomipramine, amoxapine), selective serotonin 
reuptake inhibitors (e.g. citalopram, dapoxetine) and atypical antidepressants (e.g. buproprion) 
Medicines for mental problems (e.g. haloperidol, carbamazapine, chlorpromazine, clozapine) 
Medicines to treat Parkinson's disease - anticholinergics (e.g. trihexylphenidyl, mesylate), MAO-B 
inhibitors (e.g. selegiline, deprenyl), COMT inhibitors (e.g. entacapone) 
Medicines to treat allergies - antihistamines (e.g. terfenadine, astemizole, cimetidine) 
Medicines to relax your muscles - (e.g. mivacurium, pipercurium, suxamethonium) 
Sedatives (e.g. barbiturates) </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>FIRDAPSE should not be used if you are pregnant. You must use effective contraception throughout 
the treatment. If you discover that you are pregnant during the treatment, inform your doctor 
immediately.  </p>
<p>It is not known whether FIRDAPSE is excreted in human breast milk. You and your doctor should 
discuss the risks and benefits of continuing to take FIRDAPSE while breastfeeding. </p>
<p>Driving and using machines 
This medicine may cause drowsiness, dizziness, fits (convulsions) and blurred vision, which may 
affect your ability to drive or use machines. Do not drive or operate machines if you experience these 
side effects. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take firdapse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take firdapse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or 
pharmacist if you are not sure. </p>
<p>The dose you should take is established by your doctor based on the intensity of your symptoms and 
certain genetic factors. This dose suits you only. </p>
<p>The starting dose is 5 mg amifampridine (half a tablet) three times daily (i.e. 15 mg per day). Your 
doctor may increase this dose slowly first to 5 mg (half a tablet) four times daily (i.e. 20 mg per day). 
Then your doctor may continue to increase your total daily dose adding 5 mg (half a tablet) per day, 
every 4 or 5 days.  </p>
<p>The maximum recommended dose is 60 mg per day (i.e. a total of six tablets to be taken at intervals 
during the day). Total daily doses above 20 mg should be divided into two to four separate doses. No 
single dose should exceed 20 mg (two tablets). </p>
<p>The tablets have a score-line to allow them to be broken in half. The tablets should be swallowed with 
some water and are to be taken with food. </p>
<p>Patients with liver/kidney problems: 
FIRDAPSE should be used with caution in patients with liver or kidney problems. A starting dose 
of 5 mg (half tablet) FIRDAPSE daily is recommended in patients with moderate or severe liver or 
kidney problems. For patients with mild liver or kidney problems a starting dose of 10 mg (5 mg twice 
a day) FIRDAPSE daily is recommended. For these patients the dose of FIRDAPSE should be 
increased more slowly than in those without liver or kidney problems with doses increased in 5 mg 
increments every 7 days. If any side effects occur, please consult your doctor as you may need to stop 
increasing the dose. </p>
<p>If you take more FIRDAPSE than you should 
If you take more FIRDAPSE than you should have, you may suffer from vomiting or a stomach ache. 
If you experience any of these symptoms, you should contact your doctor or pharmacist immediately. </p>
<p>If you forget to take FIRDAPSE 
If you forget to take FIRDAPSE, do not take a double dose to make up for the dose you have forgotten 
but continue to take your treatment as prescribed by your doctor. </p>
<p>If you stop taking FIRDAPSE 
If the treatment is stopped, you may experience symptoms such as tiredness, slow reflexes and 
constipation. Do not stop treatment without consulting your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Stop the treatment and immediately consult your doctor in the event of: 
Fits (convulsions) 
Asthma </p>
<p>Very common side effects which may affect more than 1 in 10 people are: 
Tingling and numbness around the mouth and extremities (such as feet and hands) 
Reduced sense of touch or sensation 
Nausea 
Dizziness 
Increase sweating, cold sweat </p>
<p>Common side effects which may affect up to 1 in 10 people are: 
Stomach ache<br />
Cold hands and feet </p>
<p>Other side effects are: 
The intensity and incidence of most side effects depends on the dose you are taking. The following 
side effects have also been reported (frequencies cannot be estimated from the available data): 
Raynaud's syndrome (circulation disorder affecting the fingers and toes) 
Diarrhoea 
Fits (convulsions) 
Cough, excessive or viscous mucus in the breathing passage, asthma attack in asthmatic patients or 
patients with a history of asthma 
Blurred vision 
Heart rhythm disorders, fast or irregular heartbeats (palpitations) 
Weakness, tiredness, headache<br />
Anxiety, sleep disorders, drowsiness 
Chorea (movement disorder), myoclonia (muscle spasm or twitching) 
Increase in certain liver enzymes (transaminases) seen on blood tests </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store firdapse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store firdapse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry 
date refers to the last day of that month. </p>
<p>Do not store above 30 C. Store in the original package, in order to protect from light and moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What FIRDAPSE contains 
The active substance is amifampridine. Each tablet contains amifampridine phosphate equivalent 
to 10 mg of amifampridine. 
The other ingredients are microcrystalline cellulose, anhydrous colloidal silica and calcium stearate. </p>
<p>What FIRDAPSE looks like and contents of the pack 
White, round tablet, flat-faced on one side and scored on the other side. 
The tablets can be divided into equal halves. 
Perforated unit dose thermoformed blisters (Thermoformed aluminium-PVC/PVDC laminate sheets) 
containing 10 tablets. 
One box contains 100 tablets comprising 10 strips with 10 tablets each. </p>
<p>Marketing Authorisation Holder 
SERB S.A.<br />
Avenue Louise 1050 Bruxelles 
Belgium </p>
<p>Manufacturers 
EXCELLA GmbH &amp; Co KG 
N rnberger Strasse 90537 Feucht<br />
Germany </p>
<p>SERB S.A.<br />
Avenue Louise 1050 Bruxelles 
Belgium  </p>
<p>This leaflet was last revised in  </p>
<p>This medicine has been authorised under  Exceptional Circumstances . This means that because of the 
rarity of this disease it has been impossible to get complete information on this medicine. 
The European Medicines Agency will review any new information on the medicine every year and 
this leaflet will be updated as necessary. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-8e3f73294a020fb836dccebb0eb47004
InstanceOf: CompositionUvEpi
Title: "Composition for firdapse Package Leaflet"
Description:  "Composition for firdapse Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8e3f73294a020fb836dccebb0eb47004)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - firdapse"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage FIRDAPSE 
3. Sådan skal du tage FIRDAPSE 
4. Bivirkninger 
5. Opbevaring<br />
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What firdapse is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What firdapse is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>FIRDAPSE anvendes til behandling af voksne for symptomer på en sygdom, der kaldes 
Lambert-Eatons syndrom, som påvirker nerver og muskler. Denne sygdom medfører forstyrrelse i 
overføringen af nerveimpulser til musklerne, hvilket resulterer i muskelsvaghed. Den kan være 
sammenkoblet med visse tumortyper (paraneoplastisk form af Lambert-Eatons syndrom) eller fravær 
af sådanne tumorer (ikke-paraneoplastisk form for Lambert-Eatons syndrom). </p>
<p>Hos patienter, som lider af denne sygdom mindskes frigivelsen af et kemisk stof kaldet acetylcholin, 
som normalt formidler nerveimpulser til musklerne, og musklerne kan ikke modtage nogle af eller alle 
signalerne fra nerven.  </p>
<p>FIRDAPSE virker ved at øge frigivelsen af acetylcholin og hjælper musklen til at modtage 
nervesignalerne. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take firdapse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take firdapse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke FIRDAPSE 
Hvis du er allergisk over for amifampridin eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6). 
Hvis du har ukontrolleret astma 
Hvis du har epilepsi, 
Sammen med lægemidler, der kan ændre dit hjertes elektriske aktivitet (Forlænget QT-interval - 
påvises ved elektrokardiogram), såsom: 
Sultroprid (et lægemiddel til behandling af visse adfærdsforstyrrelser hos voksne) 
Lægemidler mod hjerterytmeforstyrrelser (f.eks. disopyramid)<br />
Lægemidler til behandling af fordøjelsesproblemer (f.eks. cisaprid, domperidon) 
Lægemidler til behandling af infektioner - antibiotika (f.eks. rifampicin) og lægemidler til behandling 
af svampeinfektioner (f.eks. ketoconazol) 
Sammen med lægemidler, som har en terapeutisk dosis, som ligger tæt på den maksimale sikre dosis 
Hvis du har medfødte hjerteproblemer (medfødt QT-syndrom). </p>
<p>Spørg lægen eller apoteket til råds, hvis du er tvivl. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apoteketspersonalet, før du tager FIRDAPSE. </p>
<p>Fortæl det til lægen, hvis du har:<br />
Astma 
Tidligere har haft anfald (kramper) 
Nyreproblemer 
Leverproblemer </p>
<p>Din læge vil nøje holde øje med, hvordan FIRDAPSE påvirker dig, og vil måske være nødt til at 
ændre den dosis, du tager. Din læge vil også holde øje med dit hjerte ved behandlingens begyndelse og 
derefter hvert år. </p>
<p>Hvis du har Lambert-Eatons syndrom, men ikke har kræft, vil din læge foretage en grundig vurdering 
af din potentielle risiko for at udvikle kræft ved brug af FIRDAPSE, inden behandlingen indledes. </p>
<p>Fortæl det til alle læger, du konsulterer, at du tager FIRDAPSE. </p>
<p>Stop behandlingen og kontakt straks lægen i tilfælde af: 
Anfald (kramper) 
Astma </p>
<p>Brug af anden medicin sammen med FIRDAPSE 
Fortæl det altid til lægen, hvis du tager anden medicin eller har gjort det for nylig. </p>
<p>Visse lægemidler kan reagere med FIRDAPSE ved samtidig indtagelse. Følgende lægemidler må ikke 
tages samtidig med FIRDAPSE:<br />
Lægemidler, der kan ændre dit hjertes elektriske aktivitet (Forlænget QT-interval - påvises ved 
elektrokardiogram) f.eks. sultoprid, disopyramid, cisaprid, domperidon, rifampicin, og ketoconazol (se 
“ Tag ikke FIRDAPSE") </p>
<p>Det er særlig vigtigt at tale med din læge, hvis du tager et af følgende lægemidler eller har planer om 
at tage følgende lægemidler: 
Malariamedicin (f.eks. halofantrin og mefloquin) 
Tramadol (et smertestillende middel) 
Antidepressiv medicin - tricykliske antidepressiver (f.eks. clomipramin, amoxapin), selektive 
serotonin-genoptagelseshæmmere (f.eks. citalopram, dapoxetin) og atypiske antidepressiva (f.eks. 
bupropion) 
Lægemidler mod mentale problemer (f.eks. haloperidol, carbamazepin, chlorpromazin, clozapin) 
Lægemidler til behandling af Parkinsons sygdom - antikolinerge midler (f.eks. trihexylphenidyl, 
mesylat), MAO-B-hæmmere (f.eks. selegilin, deprenyl), COMT-hæmmere (f.eks. entacapon). 
Lægemidler til behandling af allergi - antihistaminer (f.eks. terfenadin, astemizol, cimetidin) 
Muskelafslappende lægemidler (f.eks. mivacurium, pipercurium, suxamethonium) 
Beroligende midler (f.eks. barbiturater) </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel.  </p>
<p>FIRDAPSE må ikke bruges under graviditet. Du skal bruge sikker prævention under hele 
behandlingen. Hvis du under behandlingen opdager, at du er gravid, skal du straks fortælle det til din 
læge.  </p>
<p>Det vides ikke, om FIRDAPSE udskilles i human brystmælk. Du og din læge bør tale sammen om 
fordele og ulemper ved fortsat at tage FIRDAPSE, mens du ammer. </p>
<p>Trafik- og arbejdssikkerhed 
Denne medicin kan forårsage døsighed, svimmelhed, anfald (kramper) og sløret syn, som kan påvirke 
din evne til at føre motorkøretøj eller betjene maskiner. Kør ikke bil eller motorcykel, og lad være med 
at cykle eller arbejde med værktøj eller maskiner, hvis du oplever disse bivirkninger. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take firdapse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take firdapse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller på apoteket. </p>
<p>Lægen anviser, hvor stor en dosis du skal tage, på baggrund af intensiteten af dine symptomer og visse 
genetiske faktorer. Denne dosis er tilpasset specielt til dig. </p>
<p>Startdosis er 5 mg amifampridin (en halv tablet) tre gange dagligt (dvs. 15 mg/dag). Lægen kan øge 
denne dosis langsomt, først til 5 mg (en halv tablet) fire gange dagligt (dvs. 20 mg/dag), og derefter 
kan lægen fortsætte med at øge den daglige dosis med 5 mg (en halv tablet) om dagen hver 4. eller 
hver 5. dag.  </p>
<p>Den maksimale, anbefalede dosis er 60 mg/dag (dvs. i alt seks tabletter, som tages jævnt fordelt over 
dagen). Daglige doser på over 20 mg bør opdeles i to til fire separate doser. En enkelt dosis bør ikke 
overstige 20 mg (to tabletter). </p>
<p>Tabletterne har en særlig delekærv, så de nemt kan brækkes over i to halvdele. Tabletterne synkes med 
lidt vand og skal indtages sammen med mad. </p>
<p>Patienter med lever-/nyreproblemer: 
FIRDAPSE skal anvendes med forsigtighed til patienter med nyre- eller leverproblemer. Der anbefales 
en startdosis på 5 mg (en halv tablet) FIRDAPSE dagligt til patienter med moderate eller alvorlige 
nyre- eller leverproblemer. Der anbefales en startdosis på 10 mg (5 mg to gange dagligt) FIRDAPSE 
dagligt til patienter med milde nyre- eller leverproblemer. Hos disse patienter bør dosis af FIRDAPSE 
øges langsommere end hos patienter uden nyre- eller leverproblemer, og doserne bør øges med 5 mg 
hver 7. dag. Henvend dig straks til lægen, hvis der opstår bivirkninger, da du måske skal stoppe med at 
øge dosis. </p>
<p>Hvis du har taget for meget FIRDAPSE 
Hvis du har taget for meget FIRDAPSE, kan du kaste op eller få ondt i maven. Fortæl det straks til 
lægen eller apoteket, hvis du oplever et eller flere af disse symptomer. </p>
<p>Hvis du har glemt at tage FIRDAPSE 
Hvis du glemmer at tage FIRDAPSE, må du ikke tage en dobbeltdosis som erstatning for den glemte 
dosis, men skal fortsætte behandlingen som anvist af lægen. </p>
<p>Hvis du holder op med at tage FIRDAPSE 
Du kan opleve symptomer som f.eks. træthed, langsomme reflekser og forstoppelse, hvis behandlingen 
stoppes. Stop ikke behandlingen uden at have talt med din læge. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Stop behandlingen og kontakt straks lægen i tilfælde af: 
Anfald (kramper) 
Astma </p>
<p>Meget almindelige bivirkninger, som kan påvirke mere end 1 ud af 10 personer, er: 
Snurren og følelsesløshed omkring munden og lemmerne (f.eks. fødder og hænder)<br />
Reduceret berøringssans eller fornemmelse 
Kvalme 
Svimmelhed 
Øget svedafsondring, koldsved </p>
<p>Almindelige bivirkninger, som kan påvirke op til 1 ud af 10 personer er: 
Mavepine 
Kolde hænder og fødder </p>
<p>Andre bivirkninger er: 
Intensiteten og forekomsten af de fleste bivirkninger er afhængig af dosis. Følgende bivirkninger er 
også set (hyppigheden kan ikke beregnes ud fra de tilgængelige data): 
Raynauds syndrom (kredsløbslidelse, der rammer fingre og tæer) 
Diarré 
Anfald (kramper) 
Hoste, øget eller viskøs slim i luftvejene, astmaanfald hos astmapatienter eller patienter, der tidligere 
har haft astma 
Sløret syn 
Hjerterytmeforstyrrelser, hurtige eller uregelmæssige hjerteslag (palpitationer) 
Svaghed, træthed, hovedpine 
Angst, søvnforstyrrelser, døsighed 
Chorea (bevægelsesforstyrrelse), myokloni (muskelspasme eller muskeltrækninger) 
Øget niveau af visse leverenzymer (transaminaser), der ses i blodprøver </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store firdapse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store firdapse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. Opbevares i den originale yderpakning for at 
beskytte mod lys og fugt. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>FIRDAPSE indeholder<br />
Aktivt stof: amifampridin. Hver tablet indeholder amifampridinphosphat svarende til 10 mg 
amifampridin. 
Øvrige indholdsstoffer: mikrokrystallinsk cellulose, kolloid vandfri silica og calciumstearat. 
Udseende og pakningsstørrelse 
Hvid, rund tablet med én flad side og delekærv på den anden side. 
Tabletterne kan deles i to lige store halvdele. 
Perforerede, termoformede dosisblisterplader (termoformede aluminium/PVC/PVDC laminatplader) 
indeholdende 10 tabletter. 
En æske indeholdende 100 tabletter bestående af 10 plader med hver 10 tabletter. 
Indehaver af markedsføringstilladelsen 
SERB S.A.<br />
Avenue Louise 480 <br />
1050 Bruxelles 
Belgien 
Fremstiller 
EXCELLA GmbH &amp; Co. KG 
Nürnberger Strasse 90537 Feucht 
Tyskland 
SERB S.A.<br />
Avenue Louise 480<br />
1050 Bruxelles 
Belgien 
Denne indlægsseddel blev senest ændret 
Dette lægemiddel er godkendt under “særlige omstændigheder". Det betyder, at det ikke har været 
muligt at opnå fuldstændig dokumentation for lægemidlet, fordi det anvendes til en sjælden sygdom. 
Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og denne 
indlægsseddel vil om nødvendigt blive ajourført. 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8e3f73294a020fb836dccebb0eb47004
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for firdapse Package Leaflet for language en"
Description: "ePI document Bundle for firdapse Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8e3f73294a020fb836dccebb0eb47004"
* entry[0].resource = composition-en-8e3f73294a020fb836dccebb0eb47004

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8e3f73294a020fb836dccebb0eb47004"
* entry[=].resource = mp8e3f73294a020fb836dccebb0eb47004
                            
                    
Instance: bundlepackageleaflet-da-8e3f73294a020fb836dccebb0eb47004
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for firdapse Package Leaflet for language da"
Description: "ePI document Bundle for firdapse Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8e3f73294a020fb836dccebb0eb47004"
* entry[0].resource = composition-da-8e3f73294a020fb836dccebb0eb47004

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8e3f73294a020fb836dccebb0eb47004"
* entry[=].resource = mp8e3f73294a020fb836dccebb0eb47004
                            
                    



Instance: mp8e3f73294a020fb836dccebb0eb47004
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product FIRDAPSE 10 mg tablets"
Description: "FIRDAPSE 10 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/601/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "FIRDAPSE 10 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 8e3f73294a020fb836dccebb0eb47004ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "firdapse"

* status = #current
* mode = #working

* title = "List of all ePIs associated with firdapse"

* subject = Reference(mp8e3f73294a020fb836dccebb0eb47004)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#firdapse "firdapse"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8e3f73294a020fb836dccebb0eb47004) // firdapse en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8e3f73294a020fb836dccebb0eb47004) // firdapse da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8e3f73294a020fb836dccebb0eb47004
InstanceOf: List

* insert 8e3f73294a020fb836dccebb0eb47004ListRuleset
    